Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1194-1197

  Studdiford, James ^a   Lamb, Kathleen ^b   Horvath, Kedron ^a   Altshuler, Marc ^a   Stonehouse, Amber ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adverse effect; Human papilloma virus (HVP) vaccine; Lymph node; Supraclavicular lymphadenopathy

Indexed keywords

WART VIRUS VACCINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; LYMPHADENOPATHY; PHYSICAL EXAMINATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LYMPH NODES; LYMPHATIC DISEASES; PAPILLOMAVIRUS VACCINES; SENTINEL LYMPH NODE BIOPSY;

EID: 51849141344     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1194     Document Type: Article

References (18)

1. Merck & Co., Inc. Gardasil (human papillomavirus quadravalent [types 6, 11, 16, and 18] vaccine, recombinant) prescribing information. Whitehouse Station, NJ; 2006.
2. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacol 2006;40:1344-52.
3. Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998;58:1313-20.
4. Al-Dajani N, Wootton SH. Cervical lymphadenitis, suppurative parotitis, thyroiditis, and infected cysts. Infect Dis Clin North Am 2007;21:523-41.
5. Merck & Co., Inc. Recombivax HB (hepatitis B vaccine, recombinant) prescribing information. Whitehouse Station, NJ; 2006.
6. GlaxoSmithKline. Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) prescribing information. Research Triangle Park, NC; 2007.
7. GlaxoSmithKline. Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) prescribing information. Research Triangle Park, NC; 2007.
8. GlaxoSmithKline. Fluarix (influenza virus vaccine) prescribing information. Research Triangle Park, NC; 2007.
9. Merck & Co., Inc. Varivax (varicella virus vaccine live [Oka/Merck]) prescribing information. Whitehouse Station, NJ; 2007.
10. Sanofi Pasteur Ltd. BCG Vaccine (freeze-dried) package insert. Toronto, Ontario, Canada; 2002.
11. GlaxoSmithKlein Biologicals. Engerix-B (Hepatitis B vaccine [Recombinant]) prescribing information. Research Triangle Park, NC; 2007.
12. DiMiceli L, Pool V, Kelso JM, et al. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006;24:703-7.
13. Grotto I, Mandel Y, Ephros M, et al. Major adverse reactions to yeast-derived hepatitis B vaccines: a review. Vaccine 1998;16:329-34.
14. Singleton JA, Lloyd JC, Mootrey GT, et al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1997;17:2908-17.
15. Markowitz LE, Dunne EF, Saraiya M, et al. Quadravalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2007;56:1-24.
16. World Health Organization. Global advisory committee on vaccine safety. Weekly Epidemiol Rec 2007;82:252-9.
17. Sharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. J Cancer Res Ther 2007;3:92-5.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.